• Laoise Griffin, Jennifer Boggs, Bart Ramsay, Caitriona Hackett, Kashif Ahmad, and Maeve Lynch.
• Department of Dermatology, University Hospital Limerick, Limerick, Ireland. laoisegriffin@gmail.com.
• Ir J Med Sci. 2021 May 1; 190 (2): 639-641.

AbstractSecukinumab is a novel anti-interleukin-17A agent that has achieved a 75% decrease from baseline in Psoriasis Area and Severity Index (PASI 75) in 77-81% of patients treated in clinical trials Langley et al. (N Engl J Med 371:326-338, 2014). There is limited data on the use of secukinumab outside of clinical trials. We provide real-world data on the efficacy and safety of secukinumab in patients with severe psoriasis attending an outpatient dermatology service. In our retrospective review, we demonstrate (PASI 75) a response rate of 47% in patients previously treated with multiple systemic and biologics. Our efficacy is comparable to that seen in the Signature study who examined similar populations. Response was maintained at follow-up of almost 1 year with acceptable safety data. Patients with psoriatic arthritis were more likely to remain on secukinumab than those without at last clinic follow-up.

15 keywords...

hide…